24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Blame Diabetes: Rates of 2 Nerve Conditions on the RiseElectronic Messaging Intervention Cuts Cardiovascular Risk in T2DMHealth Tip: Preventing Diabetic Foot SoresEarly Menopause May Be Tied to Type 2 DiabetesMore Than 100 Million Americans Have Diabetes or Prediabetes: CDCNT-proBNP Improves Heart Failure Prediction in T2DMStem Cell Educator Therapy May Help Fight DiabetesResistance Training Improves Microvascular Blood Flow in T2DMNew Diabetes Treatment Teaches Rogue Immune Cells to BehaveIncreased Parental Anxiety With Increased Diabetes RiskIntensive Lifestyle Changes May Up Frailty Fracture Risk in DMExercising Safely With DiabetesHyperbaric Oxygen Therapy Increasingly Being UsedTherapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 PercentT1DM Patients With Active β-Cell Function Differ ImmunologicallyMany People With Type 1 Diabetes Still Make Some InsulinTryptophan May Be Marker for Diabetic NephropathyEstimated Prevalence of Diabetes 10.9 Percent in ChinaReview Spotlights Optimal Care of T2DM + OsteoporosissRAGE Linked to Risk of Incident Diabetic NephropathyDiabetic Ketoacidosis Poses Fetal Risk During/After EventFDA Warns Diabetics Against Use of Secondhand Test StripsRisk of Cardiovascular Events Similar With, Without DiabetesPCSK9 Increased in Females, Youth With Type 1 DiabetesText Messaging Intervention Can Up Glycemic Control in T2DMGood Results for Zone MPC-Based Artificial PancreasBroccoli Extract Shows Promise for Type 2 DiabetesSleep Apnea Linked to Diabetic Retinopathy in Type 2 DiabetesADA: Canagliflozin Tied to Lower Risk of Cardiovascular EventsKey Diabetes Test Gives Higher Blood Sugar Readings in Black PatientsFor Diabetics, Nasal Powder Fixed Severe Low Blood SugarADA: Glucose Self-Monitoring Often Lacks Benefit in T2DMCan Folks With Type 2 Diabetes Forgo the Finger Stick?Sitagliptin Stimulates Distal Tubular Natriuresis in T2DMStudy Confirms Link Between Diabetes Med and Rare But Dangerous ComplicationLower HbA1c Linked to Better Diabetes-Specific HRQoL in YouthHealth Tip: What's My Target Blood Glucose?Comorbid Celiac Disease Common Among Youth With T1DMDiabetic Foot Ulcers, Infections Significantly Up Burden of CareMapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas Feasible
Links
Related Topics

Medical Disorders

What Drugs Work Best for Diabetic Nerve Pain?

HealthDay News
by -- Robert Preidt
Updated: Mar 24th 2017

new article illustration

FRIDAY, March 24, 2017 (HealthDay News) -- Nerve pain and numbness, also known as neuropathy, is a debilitating but common symptom of diabetes.

Now, new research suggests certain drugs may outperform others in treating diabetic neuropathy.

The new review of the data on the subject was led by Julie Waldfogel of Johns Hopkins Hospital in Baltimore. Her team noted that about half of people with diabetes have some form of nerve damage caused by high levels of blood sugar.

However, not all of them will have symptoms such as pain, numbness and tingling in the legs and feet.

In the new study, the Hopkins group reviewed 106 studies on pain relief for diabetic neuropathy. The researchers found "moderate" evidence that the antidepressants duloxetine (Cymbalta) and venlafaxine (Effexor) reduce diabetic nerve pain.

However, they only found "weak" evidence that botulinum toxin (Botox), the anti-seizure drugs pregabalin (Lyrica) and oxcarbazepine (Trileptal), and drugs called tricyclic antidepressants and atypical opioids (drugs such as Tramadol) may help reduce pain.

The researchers also noted that gabapentin (Neurontin, Gralise) works in a similar manner to pregabalin, and the review found gabapentin no more effective than a placebo.

Long-term use of standard opioids -- such as OxyContin, Vicodin or Percocet -- is not recommended for chronic pain due, including neuropathy, because of a lack of evidence of long-term benefit and the risk of abuse, misuse and overdose, Waldfogel said.

The anti-seizure drug valproate and capsaicin cream were also ineffective, according to the review published online March 24 in the journal Neurology.

The review was funded by the U.S. Agency for Healthcare Research and Quality.

"Providing pain relief for neuropathy is crucial to managing this complicated disease," Waldfogel said in a journal news release.

"Unfortunately, more research is still needed, as the current treatments have substantial risk of side effects, and few studies have been done on the long-term effects of these drugs," she added.

Two experts in diabetes care and pain management said the data review is important information for patients.

"This trial was a much needed step in the right direction in an otherwise murky field of medicine," said Dr. Caroline Messer, an endocrinologist at Lenox Hill Hospital in New York City.

She noted that "traditional teaching for endocrinologists has always included the use of gabapentin for diabetic neuropathy. Given gabapentin's host of side effects, it will be a relief to remove it from the toolbox."

And Messer added that "venlafaxine is now an interesting treatment possibility, given that one of its common side effects, weight loss, could prove useful for patients with type 2 diabetes."

Dr. Ajay Misra is chair of neurosciences at Winthrop-University Hospital in Mineola, N.Y. He noted that neuropathy can differ for people with type 1 or type 2 diabetes, with neuropathy levels correlating well with blood sugar management in people with type 1 disease, but not as well for those with type 2 diabetes.

As for pain relief, Misra said "there is clearly no medication which was found to be highly effective" in the new review, so there is clearly a need for research into better analgesic options for patients.

"We hope our findings are helpful to doctors and people with diabetes who are searching for the most effective way to control pain from neuropathy," researcher Waldfogel added. "Unfortunately, there was not enough evidence available to determine if these treatments had an impact on quality of life. Future studies are needed to assess this."

More information

The American Diabetes Association has more on nerve damage from diabetes.